You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
AstraZeneca
Express Scripts
Boehringer Ingelheim
Merck

Last Updated: July 14, 2020

DrugPatentWatch Database Preview

XYZAL ALLERGY 24HR Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Xyzal Allergy 24hr patents expire, and what generic alternatives are available?

Xyzal Allergy 24hr is a drug marketed by Sanofi Aventis Us and is included in two NDAs. There is one patent protecting this drug.

This drug has thirty-one patent family members in twenty-five countries.

The generic ingredient in XYZAL ALLERGY 24HR is levocetirizine dihydrochloride. There are thirteen drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the levocetirizine dihydrochloride profile page.

Paragraph IV (Patent) Challenges for XYZAL ALLERGY 24HR
Tradename Dosage Ingredient NDA Submissiondate
XYZAL ALLERGY 24HR SOLUTION;ORAL levocetirizine dihydrochloride 209090 2018-01-04

US Patents and Regulatory Information for XYZAL ALLERGY 24HR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us XYZAL ALLERGY 24HR levocetirizine dihydrochloride SOLUTION;ORAL 209090-001 Jan 31, 2017 OTC Yes Yes   Start Trial   Start Trial Y   Start Trial
Sanofi Aventis Us XYZAL ALLERGY 24HR levocetirizine dihydrochloride TABLET;ORAL 209089-001 Jan 31, 2017 OTC Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for XYZAL ALLERGY 24HR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0663828 C300085 Netherlands   Start Trial PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
0058146 2001C/045 Belgium   Start Trial PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
AstraZeneca
Express Scripts
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.